Table 2.
The main characteristics of a qualified study of tissue levels
| Author | Year | Country | Cancer type | Antibody | Survival analysis |
|---|---|---|---|---|---|
| Quan Zhou [39] | 2020 | China | gastric cancer | Abcam | OS |
| Supaporn Yangngam [40] | 2020 | Thailand | cholangiocarcinoma | R&D | OS |
| Yan Yang [10] | 2016 | China | hepatocellular carcinoma | R&D | NO |
| Kirsten D. Mertz [41] | 2015 | Switzerland | colorectal cancer | R&D | NO |
| Zewei Wang [42] | 2015 | China | renal cell carcinoma | Abcam | OS |
| Wenwei Hu [14] | 2016 | China | gastric cancer | Sigma | NO |
| Xiaoguang Tong [44] | 2015 | China | epithelial ovarian cancer | Enzo Life Sciences | OS |
| Satoshi Nagaoka [45] | 2020 | Japan | cholangiocarcinoma | NA | OS |
| Wenxiu Wang [46] | 2020 | China | hepatocellular carcinoma | R&D | OS |
| Dorothee Grama Tzki [47] | 2016 | Switzerland | gliomas | R&D | OS |
| Jianfei Zhang [48] | 2016 | China | gliomas | Proteintech | OS |
| Yihui Wen [49] | 2018 | China |
head and neck squamous cell carcinoma |
R&D | OS |
| Kazuya Ishikawa [50] | 2014 | Japan |
squamous cell carcinoma of the tongue |
R&D | OS |
| Lu Jing [32] | 2020 | China | hepatocellular carcinoma | NA | NA |
| Chen Ling [51] | 2020 | China | non-small cell lung cancer | R&D | OS |
| Zhao Lirong [52] | 2020 | China | ovarian cancer | NA | NA |
| Xia Bingxiang [38] | 2017 | China | gastric cancer | Dako | OS |
| Zhang Jianfei [53] | 2016 | China | gliomas | NA | NA |
| Huang Di [54] | 2016 | China | colorectal cancer | Abcam | OS |
| Hu Xia [37] | 2019 | China | esophageal adenocarcinoma | Proteintech | NA |
| Yue Ying [55] | 2018 | China |
esophageal squamous cell carcinomas |
Abcam | OS |
| Hu Wenwei [56] | 2018 | China | gastric cancer | NA | NA |